Takeda withdraws marketing application for insomnia drug in Europe
Takeda Global R&D Centre Europe (TGRD EU) submitted the marketing authorization application (MAA) for ramelteon in Europe in March 2007. The Committee for Medicinal Products for Human Use
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.